S. Booker

发表

Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.

D. Whittington, Matthew R. Lee, C. Dominguez, 2012, Journal of medicinal chemistry.

Nuclear localization of Dpc4 (Madh4, Smad4) in colorectal carcinomas and relation to mismatch repair/transforming growth factor-beta receptor defects.

E. Montgomery, M. Goggins, S. Kern, 2001, The American journal of pathology.

Effect of microwave heating on Ullmann-type heterocycle-aryl ether synthesis using chloro-heterocycles

C. Dominguez, R. Hungate, Tae-Seong Kim, 2006 .

CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.

I. Kariv, K. Vaddi, M. Covington, 2007, Bioorganic & medicinal chemistry letters.

Discovery of 1H-pyrazol-3(2H)-ones as potent and selective inhibitors of protein kinase R-like endoplasmic reticulum kinase (PERK).

Kristin L. Andrews, D. Powers, R. Kendall, 2015, Journal of medicinal chemistry.

Discovery and optimization of a series of benzothiazole phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors.

Daniel J. Freeman, R. Wahl, J. McCarter, 2011, Journal of medicinal chemistry.

Discovery of a covalent inhibitor of KRASG12C (AMG 510) for the treatment of solid tumors.

N. Chen, J. McCarter, K. Rex, 2019, Journal of medicinal chemistry.

Design, synthesis, and biological evaluation of potent c-Met inhibitors.

Yuan Cheng, K. Rex, A. Coxon, 2008, Journal of medicinal chemistry.

Selective class I phosphoinositide 3-kinase inhibitors: optimization of a series of pyridyltriazines leading to the identification of a clinical candidate, AMG 511.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2012, Journal of medicinal chemistry.

Structure-activity relationships of phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: investigations of various 6,5-heterocycles to improve metabolic stability.

Daniel J. Freeman, J. McCarter, Nancy Zhang, 2011, Journal of medicinal chemistry.

Structure-based design of a novel series of potent, selective inhibitors of the class I phosphatidylinositol 3-kinases.

Daniel J. Freeman, J. McCarter, D. Whittington, 2012, Journal of medicinal chemistry.

Discovery of ( R)-8-(6-Methyl-4-oxo-1,4,5,6-tetrahydropyrrolo[3,4- b]pyrrol-2-yl)-3-(1-methylcyclopropyl)-2-((1-methylcyclopropyl)amino)quinazolin-4(3 H)-one, a Potent and Selective Pim-1/2 Kinase Inhibitor for Hematological Malignancies.

K. Rex, J. Canon, B. Herberich, 2019, Journal of medicinal chemistry.

Discovery and Optimization of Quinazolinone-pyrrolopyrrolones as Potent and Orally Bioavailable Pan-Pim Kinase Inhibitors.

K. Rex, B. Herberich, Matthew R. Lee, 2016, Journal of medicinal chemistry.

Phospshoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) dual inhibitors: discovery and structure-activity relationships of a series of quinoline and quinoxaline derivatives.

Daniel J. Freeman, Hongyu Liao, Nancy Zhang, 2011, Journal of medicinal chemistry.